LENSAR (LNSR) Resumen de Acciones
LENSAR, Inc. es una empresa de dispositivos médicos en fase comercial que se dedica al diseño, desarrollo y comercialización de sistemas láser para el tratamiento de cataratas y la gestión del astigmatismo corneal preexistente o inducido quirúrgicamente en el Sistema Unido, Europa, Asia, Corea del Sur e internacionalmente. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 4/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
LNSR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de LENSAR, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$5.63 |
| Máximo en las últimas 52 semanas | US$13.47 |
| Mínimo de 52 semanas | US$5.06 |
| Beta | 0.87 |
| Cambio en 1 mes | -3.92% |
| Variación en 3 meses | -7.25% |
| Cambio de 1 año | -55.88% |
| Variación en 3 años | 32.47% |
| Variación en 5 años | -30.24% |
| Variación desde la OPV | -37.44% |
Noticias y actualizaciones recientes
LNSR: Recent Upgrade And Margin Outlook Will Drive Repricing Potential
Analysts have maintained their $8.50 price target on LENSAR, citing a modestly lower discount rate and slightly adjusted long term margin and P/E assumptions following a recent upgrade in Street research coverage. What's in the News On April 10, 2026, LENSAR reported that Chief Financial Officer Thomas R.LNSR: Post Deal Selloff Will Set Up Margin Led Repricing Potential
Analysts have lifted their price target on LENSAR to $10, citing stronger profit margin expectations, a lower assumed discount rate, and a reduced future P/E, even as projected revenue growth is now more conservative. Analyst Commentary Bullish Takeaways Bullish analysts highlight the $10 price target as reflecting confidence that LENSAR's expected profit margins can support a higher valuation multiple than previously assumed.LNSR: Buy Thesis Will Rebuild Around Post Deal Selloff And Adoption Reacceleration
Analysts have nudged their price target on LENSAR stock to $8.50, with recent upgrades to Buy and renewed confidence around the ALLY System adoption story cited as key reasons for the updated view. Analyst Commentary Recent research has focused on how the ALLY System adoption story and the fallout from the halted Alcon acquisition are shaping expectations for LENSAR’s execution and valuation.Recent updates
LNSR: Recent Upgrade And Margin Outlook Will Drive Repricing Potential
Analysts have maintained their $8.50 price target on LENSAR, citing a modestly lower discount rate and slightly adjusted long term margin and P/E assumptions following a recent upgrade in Street research coverage. What's in the News On April 10, 2026, LENSAR reported that Chief Financial Officer Thomas R.LNSR: Post Deal Selloff Will Set Up Margin Led Repricing Potential
Analysts have lifted their price target on LENSAR to $10, citing stronger profit margin expectations, a lower assumed discount rate, and a reduced future P/E, even as projected revenue growth is now more conservative. Analyst Commentary Bullish Takeaways Bullish analysts highlight the $10 price target as reflecting confidence that LENSAR's expected profit margins can support a higher valuation multiple than previously assumed.LNSR: Buy Thesis Will Rebuild Around Post Deal Selloff And Adoption Reacceleration
Analysts have nudged their price target on LENSAR stock to $8.50, with recent upgrades to Buy and renewed confidence around the ALLY System adoption story cited as key reasons for the updated view. Analyst Commentary Recent research has focused on how the ALLY System adoption story and the fallout from the halted Alcon acquisition are shaping expectations for LENSAR’s execution and valuation.LNSR: Buy Thesis Rebuilds Around Post Deal Selloff And Adoption Reacceleration
Analysts have raised their price targets on LENSAR shares to $10, citing renewed optimism around ALLY System adoption and viewing the post acquisition setback selloff as a second chance for investors. Analyst Commentary Bullish Takeaways Bullish analysts point to a $10 price target as a simple yardstick for how they frame upside potential if ALLY System adoption trends seen before the Alcon deal announcement can be re established.
Cataract Procedure Bundling Will Pressure Margins Yet Recurring Revenue Should Support Gradual Recovery
Catalysts About LENSAR LENSAR develops and commercializes robotic femtosecond laser systems for cataract surgery, with a focus on its ALLY Robotic Laser Cataract System. What are the underlying business or industry changes driving this perspective?LNSR: Buy Rating Resets Around Post Deal Selloff And Execution Rebuild
Analysts have trimmed their price target for LENSAR to $8.50 from $12.50, reflecting updated views on revenue growth, profitability and a lower future P/E, while also pointing to recent upgrades that highlight renewed interest in the stock following the failed Alcon acquisition. Analyst Commentary Recent Street research has focused on the reset expectations for LENSAR following the failed Alcon transaction, as well as the potential runway for the company’s ALLY System.
Recurring Cataract Procedure Revenue And Machine Learning Will Transform This Undervalued Medical Device Story
Catalysts About LENSAR LENSAR develops and commercializes the ALLY Robotic Laser Cataract System for laser assisted cataract surgery. What are the underlying business or industry changes driving this perspective?LNSR: Buy Rating And Post Deal Reset Will Drive Future Reassessment
Analysts have trimmed their fair value estimate for LENSAR from $15.00 to $12.50, pointing to revised assumptions around discount rates, margins, and future P/E, alongside a BTIG upgrade to Buy that highlights past ALLY System adoption and the recent post acquisition selloff as a potential second chance for investors to reassess the story. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the cut in fair value to $12.50 still sits above the current $10 price target.Global System Placements Will Improve Operating Room Efficiency
Strong system placements and contract pipelines in international markets enhance potential for sustained revenue growth and competitive advantage.Even With A 28% Surge, Cautious Investors Are Not Rewarding LENSAR, Inc.'s (NASDAQ:LNSR) Performance Completely
Despite an already strong run, LENSAR, Inc. ( NASDAQ:LNSR ) shares have been powering on, with a gain of 28% in the...We're Hopeful That LENSAR (NASDAQ:LNSR) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, LENSAR...Market Might Still Lack Some Conviction On LENSAR, Inc. (NASDAQ:LNSR) Even After 28% Share Price Boost
LENSAR, Inc. ( NASDAQ:LNSR ) shareholders would be excited to see that the share price has had a great month, posting a...LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...LENSAR, Inc. (NASDAQ:LNSR) Doing What It Can To Lift Shares
With a price-to-sales (or "P/S") ratio of 1.3x LENSAR, Inc. ( NASDAQ:LNSR ) may be sending bullish signals at the...Here's Why Shareholders May Want To Be Cautious With Increasing LENSAR, Inc.'s (NASDAQ:LNSR) CEO Pay Packet
Key Insights LENSAR to hold its Annual General Meeting on 7th of May Salary of US$541.1k is part of CEO Nick Curtis's...LENSAR, Inc.'s (NASDAQ:LNSR) Shares Leap 33% Yet They're Still Not Telling The Full Story
LENSAR, Inc. ( NASDAQ:LNSR ) shares have continued their recent momentum with a 33% gain in the last month alone...Here's Why We're Watching LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Not Many Are Piling Into LENSAR, Inc. (NASDAQ:LNSR) Just Yet
LENSAR, Inc.'s ( NASDAQ:LNSR ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy right now...Here's Why We're A Bit Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...Investors Continue Waiting On Sidelines For LENSAR, Inc. (NASDAQ:LNSR)
LENSAR, Inc.'s ( NASDAQ:LNSR ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy right now...This Broker Just Slashed Their LENSAR, Inc. (NASDAQ:LNSR) Earnings Forecasts
One thing we could say about the covering analyst on LENSAR, Inc. ( NASDAQ:LNSR ) - they aren't optimistic, having just...Will LENSAR (NASDAQ:LNSR) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Here's Why We're Not Too Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...LENSAR GAAP EPS of -$0.67, revenue of $8M
LENSAR press release (NASDAQ:LNSR): Q2 GAAP EPS of -$0.67. Revenue of $8M (+1.3% Y/Y). Adjusted EBITDA was -$4.3M for the quarter ended June 30, 2022 and -$2.3M for the quarter ended June 30, 2021. As of June 30, 2022, the company had cash and cash equivalents of $25.2M as compared to $31.6M at December 31, 2021. Based on its cash position and operational forecasts, the company believes it has sufficient cash to fund operations into 2024.LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Rentabilidad de los accionistas
| LNSR | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | -1.9% | 3.9% | -2.6% |
| 1Y | -55.9% | -20.0% | 20.0% |
Rentabilidad vs. Industria: Los resultados de LNSR fueron inferiores a los de la industria US Medical Equipment, que obtuvo un rendimiento del -20% el año pasado.
Rentabilidad vs. Mercado: LNSR obtuvo unos resultados inferiores a los del mercado US, que fueron del 20% el año pasado.
Volatilidad de los precios
| LNSR volatility | |
|---|---|
| LNSR Average Weekly Movement | 8.2% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: LNSR no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de LNSR (8%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2004 | 150 | Nick Curtis | www.lensar.com |
LENSAR, Inc. es una empresa de dispositivos médicos en fase comercial dedicada al diseño, desarrollo y comercialización de sistemas láser para el tratamiento de cataratas y la gestión del astigmatismo corneal preexistente o inducido quirúrgicamente en Estados Unidos, Europa, Asia, Corea del Sur e internacionalmente. La empresa ofrece el sistema láser LENSAR, que incorpora una serie de tecnologías patentadas diseñadas para ayudar al cirujano a obtener resultados visuales mediante la obtención de imágenes, la planificación de procedimientos, el diseño y la precisión. También ofrece el sistema láser robótico para cataratas ALLY, un sistema compacto para el tratamiento de cataratas diseñado para permitir a los cirujanos realizar intervenciones estériles de cataratas asistidas por láser en un único quirófano.
Resumen de fundamentos de LENSAR, Inc.
| Estadísticas fundamentales de LNSR | |
|---|---|
| Capitalización bursátil | US$74.32m |
| Beneficios(TTM) | US$29.40m |
| Ingresos (TTM) | US$57.70m |
¿Está LNSR sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de LNSR | |
|---|---|
| Ingresos | US$57.70m |
| Coste de los ingresos | US$31.33m |
| Beneficio bruto | US$26.38m |
| Otros gastos | -US$3.02m |
| Beneficios | US$29.40m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 2.43 |
| Margen bruto | 45.71% |
| Margen de beneficio neto | 50.94% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado LNSR a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/26 15:08 |
| Precio de las acciones al final del día | 2026/06/26 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
LENSAR, Inc. está cubierta por 3 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Michael Gorman | BTIG |
| Frank Takkinen | Lake Street Capital Markets, LLC |
| Richard Newitter | Leerink Partners LLC |